Effects of Cannabidiol on Stress and Nicotine Withdrawal
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Epidiolex.
- Who it may be relevant to
- Registry conditions: CBD, Stress, Nicotine Dependence, Tobacco Smoking. Basic parameters: 21 years — 70 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Pharmacological Effects of Cannabidiol on Responses to Stress and Nicotine Withdrawal
Overview
The purpose of this study is to examine the effect of doses of cannabidiol (CBD) during exposure to stress and nicotine withdrawal in nicotine users. The main objectives of the study include examining the effect CBD has on stress, tobacco dependence, tobacco withdrawal, and sex differences between these types of stress. Participants will be administered CBD and exposed to stress. Biological and subjective measures will be collected. Participants may be asked to stop use for 24 hours. Researchers will also investigate withdrawal effects between participants who have not smoked nicotine in 24 hours and those who have continued to smoke before each session.
Detailed description
This study will use a double-blind, placebo-controlled, within-subjects crossover design to examine the effect of acute doses of CBD during exposure to acute stress and nicotine withdrawal using a relevant set of biological and subjective measures that are known to be sensitive to acute stress and to nicotine withdrawal. There will be one in-person medical screening session, 3 pre-laboratory phone sessions, and 3 in-person experimental laboratory sessions separated by at least 72 hrs. Total duration for a study completer is estimated to be 2-3 weeks. Three doses of CBD (0mg, 200mg, and 400mg) will be administered, one at each of three separate laboratory sessions that will last approximately 5 hours each and be separated by at least 72 hours. Two effective induction challenges will be implemented: one is behavioral (an established and well validated acute psychological stress induction) and one is a nicotine withdrawal challenge (24 hours abstinence from all nicotine products). Nicotine users reporting daily cigarette use (N=90) will be recruited. Nicotine users will be randomly assigned to continue nicotine use ad libitum or to abstain for 24 hours before each of three laboratory sessions. Randomization will be stratified based on participant sex and current use of other tobacco products (e.g. e-cigarettes, smokeless tobacco, pouches, cigars/cigarillos). Participants who use other nicotine-related products (e.g., e-cigarettes) will be accepted in the study if they also smoke cigarettes. Use of other nicotine products will be assessed and tracked to account for their effects on the collected measures.
Interventions
- Drug Epidiolex
Oral cannabidiol
Primary outcome measures
- Negative Affect as assessed by the Subjective State Scale [Time frame: 20 minutes, 70 minutes, 120 minutes, 170 minutes, 190 minutes, 200 minutes, 220 minutes timepoints]
- Positive Affect as assessed by the Subjective State Scale [Time frame: 20 minutes, 70 minutes, 120 minutes, 170 minutes, 190 minutes, 200 minutes, 220 minutes timepoints]
- Blood Plasma Cortisol level [Time frame: 20 minutes, 70 minutes, 120 minutes, 170 minutes, 190 minutes, 200 minutes, 220 minutes timepoints]
- Salivary Cortisol level [Time frame: 20 minutes, 70 minutes, 120 minutes, 170 minutes, 190 minutes, 200 minutes, 220 minutes timepoints]
- Plasma Concentration of Endocannabinoids [Time frame: 20 minutes, 70 minutes, 120 minutes, 170 minutes, 190 minutes, 200 minutes, 220 minutes timepoints]
- Heart Rate (beats per minutes) [Time frame: 20 minutes, 70 minutes, 120 minutes, 170 minutes, 190 minutes, 200 minutes, 220 minutes timepoints]
- Systolic Blood Pressure (mmHg) [Time frame: 20 minutes, 70 minutes, 120 minutes, 170 minutes, 190 minutes, 200 minutes, 220 minutes timepoints]
- Diastolic Blood Pressure (mmHg) [Time frame: 20 minutes, 70 minutes, 120 minutes, 170 minutes, 190 minutes, 200 minutes, 220 minutes timepoints]
Secondary outcome measures (6)
- Subjective Pain as assessed by the McGill Pain Questionnaire short form (MPQ) [Time frame: 170 minute timepoint]
- Nicotine urge as assessed by the Questionnaire on Smoking Urges (QSU-brief) [Time frame: 20 minutes, 70 minutes, 120 minutes, 170 minutes, 190 minutes, 200 minutes, 220 minutes timepoints]
- Craving for Sweet and Rich Foods as assessed by the Questionnaire on Craving for Sweet and Rich Food, [Time frame: 200 minute timepoint]
- Hypothetical Tobacco Demand [Time frame: 200 minute timepoint]
- Sustained Attention to Response Task [Time frame: 200 minute timepoint]
- Reaction time on the N-Back Cognitive test [Time frame: 200 minute timepoint]
Eligibility criteria
Inclusion criteria
- Healthy non-treatment seeking adults aged 21-70 (inclusive).
- Use of > 5 cigarettes per day for > 2 years. (Use of other tobacco/nicotine products in addition to cigarettes will be acceptable).
- Biological confirmation of cigarette use: have an expired carbon monoxide (CO) level > 8 ppm.
- Alcohol Use: < 2 drinks/day on average (< 14 drinks/week).
- Sleep schedule: No graveyard or third shift work (i.e., participants must report a normal nighttime sleep schedule).
- For women of children bearing potential and men with female partners of child-bearing potential, must be willing to use an effective form of contraception during the study and for at least 30 days after the last study drug administration.
Exclusion criteria
- Report current intention to reduce or quit cannabis or tobacco use within the next 30 days
- Meet Diagnostic and Statistical Manual (DSM-5) criteria for a substance use disorder other than alcohol, cannabis, or nicotine
- Test positive for illicit drugs other than cannabis
- Positive breath alcohol test (>.01 g/210L) at study admission
- Have a current physical or mental illness or takes a medication judged by the study team to negatively impact participant safety or scientific integrity
- Have a resting heart rate >100, systolic blood pressure >160mmHg or <100mmHg, or diastolic blood pressure >100mmHg or <50mmHg at screening.
- Have cold intolerance or a medical condition that might be exacerbated by exposure to cold (e.g. Reynaud's, peripheral neuropathy, trigeminal neuralgia, poorly controlled/uncontrolled hypothyroidism).
- Are currently pregnant, planning to become pregnant in the next three months, or are currently breastfeeding
- Have a history of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina, Raynaud's).
- Have a history of and/or current liver disease, or elevated serum liver transaminase (AST or ALT) above 3 x Upper Limit of Normal (ULN), or elevated bilirubin above 2 x ULN at screening.
- Are currently enrolled in another clinical trial or have received any drug as part of a research study within 30 days of study participation.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple blind
- Primary purpose
- Other
Study locations
United States · 1 center
- Behavioral Pharmacology Research Unit — Baltimore
Identifiers
NCT: NCT07001930 · IRB00440948 · R01DA027232-09A1